CSI Market
Sign In | Register

Fate Therapeutics Inc (FATE) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access FATE Annual Cash Flow →
Changes in quarterly cash flow trends offer perspective on how Fate Therapeutics Inc funds operations, investments, and shareholder returns.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-61.37
Depreciation & amortization5.70
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Impairment of Long-Lived Assets Held-for-use0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation7.45
Income (Loss) from Equity Method Investments0.00
Paid-in-Kind Interest0.00
Initial Fair Value And Adjustment Of Exchangeable Shares-
Debt Conversion Converted Instrument Amount-
Deferred Revenue Expense-
Stock Based Milestone Charges And Change In Fair Value Of Exchangeable Shares-
Write Off Of Deferred Debt Issuance Cost-
Increase Decrease In Contract With Customer Liability0.20
Capitalized Contract Cost Amortization-
Increase Decrease In Right Of Use Assets And Lease Liabilities Net-0.53
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-0.21
Increase (Decrease) in Accounts Payable and Accrued Liabilities-4.52
Accrued Expense0.00
Recognition of Deferred Revenue0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.65
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net1.54
Payments for (Proceeds from) Other Operating Activities-2.18
Discontinued operations0.00
Net Cash flow from Operating Activities-54.26
Investing Activities
Capital Expenditures-0.32
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments38.46
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities38.14
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.41
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net1.32
Net Proceeds From Issuance Initial Public Offering-
Sale Of Stock Consideration Received On Transaction-
Proceeds From Public Offering Of Common Stock Net Of Offering Costs-
Proceeds From Sale Of Common Stock To Collaborative Partner-
Proceeds From C I R M Award-
Proceeds From Issuance Of Pre Funded Warrants Net Of Issuance Costs-
Proceeds From Public Offering Of Common Stock And Issuance Of Pre Funded Warrants-
Proceeds From F T Eight One Nine C I R M Award-
Proceeds From F T Eight Three Six C I R M Award-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities1.74
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-54.58
Total Cash Flow-14.38
4 historic quarters locked

Sign in to unlock the full Fate Therapeutics Inc cash flow history.

Sign In Create Free Account

About Fate Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-347988

Figures are derived from filed reports and may be restated. Historical data is subject to revision.